SCHEMBL120911

SCHEMBL120911

CCCCCc1ccc(/C=C/[C@H](O)[C@@H](CO)NC)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 10/20 1.00
SPHK2 Q9NRA0 2/20 1.00
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TRPM2 O94759 2/20 0.40
CYSLTR2 Q9NS75 2/20 0.40
CYSLTR1 Q9Y271 2/20 0.40
ASAH2 Q9NR71 1/20 0.40
TRPA1 O75762 1/20 0.40
PLA2G1B P04054 1/20 0.40
TRPM8 Q7Z2W7 1/20 0.40
ESR1 P03372 2/20 0.40
ADRA2A P08913 2/20 0.40
ADORA3 P0DMS8 2/20 0.40
TACR2 P21452 2/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14633002 1.00 SPHK1 (1.00) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL20592376 1.00 SPHK1 (1.00) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL18194573 1.00 SPHK1 (1.00) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL20596127 1.00 SPHK1 (1.00) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL23519479 0.99 SPHK1 (0.97) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL13896120 0.91 SPHK1 (0.83) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL12450365 0.88 SPHK1 (0.79) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL13499031 0.88 SPHK1 (0.79) SPHK1SPHK2
SCHEMBL20168989 0.87 SPHK1 (0.77) SPHK1SPHK2CYP3A4CYP2D6CYP2C9
SCHEMBL22861894 0.87 SPHK1 (0.77) SPHK1SPHK2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP claimed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 EP claimed
EP-4291562-B1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-10 EP claimed
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-02-13 US claimed
US-20250049780-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 US claimed
EP-3810285-B1 SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS ENZO BIOCHEM INC (US) 2025-02-12 EP claimed
WO-2025006568-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2025-01-02 WO claimed
US-12070455-B2 Thienopyrrole compounds GILEAD SCIENCES, INC. (US) 2024-08-27 US claimed
EP-4398989-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-07-17 EP claimed
CN-117957234-A Thienopyrrole compounds 吉利德科学公司 2024-04-30 CN claimed
EP-4036583-A1 TARGETING KINASES FOR THE TREATMENT OF CANCER METASTASIS Board of Regents, The University of Texas System (US) 2022-08-03 EP claimed
WO-2022140325-A1 6-SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO claimed
WO-2022140326-A1 SUBSTITUTED INDOLE COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-06-30 WO claimed
WO-2022015348-A1 SPHINGOID COMPOUNDS FOR USE IN PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION Harbins Ruhr Bioscience, Inc. (US) 2022-01-20 WO claimed
EP-3863616-A2 SPHINGOID COMPOUNDS FOR USE IN THE PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION Harbins Ruhr Bioscience, Inc. (US) 2021-08-18 EP claimed
US-20180110757-A1 METHODS OF TREATING PRURITIS AND PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-04-26 US claimed
US-20170252311-A1 SPHINGOSINE KINASE INHIBITORS AND CERAMIDE FOR MAINTENANCE THERAPY OF GLIOBLASTOMA SIGNPATH PHARMA INC. 2017-09-07 US claimed
US-20150126564-A1 MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2015-05-07 US claimed
US-20140056917-A1 FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death IMMUNOMEDICS, INC. (US) 2014-02-27 US claimed
WO-2012166859-A2 MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) 2012-12-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049780-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 SPHK1 187/4885SPHK2 113/4885CYP3A4 2014/4885
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME DUSP2, MKNK2, DUSP22 SPHK1 857/4885SPHK2 159/4885CYP3A4 4634/4885
US-12070455-B2 Thienopyrrole compounds SSB, TPMT, LCP2 SPHK1 187/4885SPHK2 113/4885CYP3A4 2014/4885
US-20180110757-A1 METHODS OF TREATING PRURITIS AND PAIN CYSLTR2, LTB4R2, CYSLTR1 SPHK1 1041/4885SPHK2 903/4885CYP3A4 4131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.